### Guideline Page and Request

**OV-D**

External Request:
Submission by AstraZeneca Pharmaceuticals to consider inclusion of olaparib as:

1. An acceptable targeted recurrence therapy as a single-agent maintenance therapy in platinum-sensitive disease in response to the last platinum therapy.

2. An acceptable single-agent targeted therapy in patients having received at least three prior lines of chemotherapy.

### Panel Discussion

1. Based on the data in the noted references and discussion, the panel consensus was not to add olaparib as a single-agent maintenance therapy for platinum-sensitive disease at this time. The panel is awaiting further data on olaparib in this setting.

2. Based on the data in the noted reference and discussion, the panel consensus was to add olaparib as an acceptable recurrence therapy option on OV-D. This was listed as a targeted therapy for platinum-sensitive or platinum-resistant disease, as a category 2A recommendation. The following footnote was included with this addition:
   - "For patients with deleterious germline BRCA-mutated (as detected by an FDA-approved test or other validated test performed in a CLIA-approved facility) advanced ovarian cancer who have been treated with three or more lines of chemotherapy."

### References


### Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>